Anwen Xiong - Department of Medical OncologyShanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 50 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Camrelizumab Plus Nab-Paclitaxel and Carboplatin As First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial

Jia Yu,Anwen Xiong,Lei Wang,Xinlong Zheng,Tao Jiang,Qi Wang,Bin Chen,Menghang Yang,Wei Li, Jiajia Yuan, Changhong Zhao,Xiaohui Chen,Caicun Zhou,Shengxiang Ren

crossref（2024）

引用0浏览0引用

Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: the Phase II TRUST-I Study

Wei Li,Anwen Xiong,Nong Yang,Huijie Fan,Qitao Yu,Yanqiu Zhao,Yongsheng Wang,Xue Meng,Jingxun Wu,Ziping Wang,Yunpeng Liu,Xicheng Wang,Xintian Qin,Kaihua Lu,Wu Zhuang, Yizhong Ren, Xianyu Zhang, Bing Yan,Christine M. Lovly,Caicun Zhou

JOURNAL OF CLINICAL ONCOLOGYno. 22 (2024)

引用0浏览0WOS引用

Prognostic Role of Dynamic Changes in Inflammatory Indicators in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors—a Retrospective Cohort Study

Liang Guo,Juanjuan Li,Jing Wang,Xinru Chen,Chenlei Cai, Fei Zhou,Anwen Xiong

TRANSLATIONAL LUNG CANCER RESEARCHno. 8 (2024): 1975-1987

引用0浏览0WOS引用

Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1+ Non–small Cell Lung Cancer: the Phase 2 TRUST-I Study

Wei Li,Anwen Xiong,Nong Yang,Huijie Fan,Qitao Yu, Yanqiu Zhao,Yongsheng Wang, Xue Meng,Jingxun Wu,Ziping Wang,Yunpeng Liu,Xicheng Wang,Xintian Qin,Kaihua Lu,Wu Zhuang, Yizhong Ren, Xianyu Zhang, Bing Yan,Christine M. Lovly,Caicun Zhou

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Camrelizumab Plus Famitinib in Previously Chemo-Immunotherapy Treated Patients with Advanced NSCLC: Results from an Open-Label Multicenter Phase 2 Basket Study

CANCER IMMUNOLOGY IMMUNOTHERAPYno. 7 (2024)

引用0浏览0WOS引用

Comprehensive analysis of clinicopathological profiles in adenosquamous carcinoma of the lung

Yuanyuan Wang,Haoyue Guo,Likun Hou, Yuhan Wu,Xuefei Li,Chao Zhao,Lei Cheng,Anwen Xiong

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH（2024）

引用0浏览0WOS引用

Efficacy and Safety of SY-5007, a Highly Potent and Selective RET Inhibitor, in Chinese Patients with Advanced RET-fusion Positive Non-Small Cell Lung Cancer (NSCLC): Results from a Multicenter, Single-Arm, Phase II Study

Anwen Xiong,XingYa Li,Nong Yang, Xiangjiao Meng,Qitao Yu, Liping Tan,Qiming Wang,Yongsheng Wang,Baogang Liu,Hui Luo,Ying Wang, Dingzhi Huang,Yiping Zhang, Zhengbo Song,Feng Ye,Jian Fang, Mingfang Zhao,Yinghui Sun,Caicun Zhou

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Spatial Multi-Omics Revealed the Impact of Tumor Ecosystem Heterogeneity on Immunotherapy Efficacy in Patients with Advanced Non-Small Cell Lung Cancer Treated with Bispecific Antibody

Xinyu Song,Anwen Xiong,Fengying Wu,Xuefei Li, Jing Wang,Tao Jiang,Peixin Chen,Xiaoshen Zhang, Zhikai Zhao,Huifang Liu,Lei Cheng, Chao Zhao,Zhehai Wang,Chaohu Pan, Xiaoli Cui, Ting Xu,Haitao Luo,Caicun Zhou

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2023）

引用8浏览0引用

Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study

Anwen Xiong,Wei Li,Xingya Li,Yun Fan,Zhiyong Ma,Jian Fang, Qiang Xie,Wu Zhuang,Mafei Kang, Jing Wang, Ting Xu, Mo Xu,Lihua Zhi,Qing Liu, Ni Wang,Caicun Zhou

European Journal of Cancer (2023): 112936-112936

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn